This review aggregates evidence of therapy for clinicians and sheds light on comparative efficacies of alternative LN treatments. As more promising agents are entering the market, such as voclosporin, belimumab, and obinutuzumab, LN management might undergo significant changes during the next years.
Ferrán Catalá-López, Brian Hutton, Amparo Núñez-Beltrán, Matthew J. Page, Manuel Ridao-López, Diego Macías Saint-Gerons, Miguel Catalá, Rafael Tabarés‐Seisdedos, David Moher
Discussion(0)
No comments yet. Be the first to comment.